KBC Group’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,726
Closed -$915K 1572
2022
Q3
$915K Buy
3,726
+59
+2% +$15.9K ﹤0.01% 681
2022
Q2
$908K Hold
3,667
﹤0.01% 676
2022
Q1
$1.22M Buy
3,667
+224
+7% +$69K ﹤0.01% 670
2021
Q4
$1.24M Sell
3,443
-3,188
-48% -$1.08M ﹤0.01% 689
2021
Q3
$2.16M Hold
6,631
0.01% 650
2021
Q2
$2.07M Hold
6,631
0.01% 663
2021
Q1
$2.11M Hold
6,631
0.01% 642
2020
Q4
$2.15M Hold
6,631
0.01% 627
2020
Q3
$1.84M Buy
6,631
+464
+8% +$134K 0.01% 612
2020
Q2
$1.49M Buy
6,167
+737
+14% +$148K 0.01% 620
2020
Q1
$788K Sell
5,430
-16,743
-76% -$2.78M 0.01% 750
2019
Q4
$3.78M Sell
22,173
-373
-2% -$69.2K 0.02% 529
2019
Q3
$4.01M Buy
22,546
+3,467
+18% +$749K 0.03% 487
2019
Q2
$4.97M Buy
19,079
+362
+2% +$96K 0.04% 438
2019
Q1
$5.35M Sell
18,717
-2,281
-11% -$758K 0.04% 405
2018
Q4
$6.83M Sell
20,998
-1,558
-7% -$541K 0.08% 285
2018
Q3
$10.1M Buy
22,556
+2,938
+15% +$1.16M 0.08% 291
2018
Q2
$8.03M Buy
+19,618
New +$7.11M 0.07% 327
2017
Q2
Sell
-3,097
Closed -$388K 1345
2017
Q1
$388K Buy
+3,097
New +$359K ﹤0.01% 1094
2016
Q1
Sell
-16,302
Closed -$1.47M 1312
2015
Q4
$1.47M Buy
16,302
+5,220
+47% +$443K 0.03% 538
2015
Q3
$1.03M Buy
+11,082
New +$976K 0.02% 592
2015
Q2
Sell
-24,068
Closed -$1.72M 1430
2015
Q1
$1.72M Buy
+24,068
New +$1.31M 0.02% 592

Other funds holding ABMD

KBC Group's ABMD Position: Q4 2022 in Review

KBC Group sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 3,726 shares — an estimated $915K sold.

KBC Group first reported a position in ABMD in Q1 2015 and held it in 22 quarters. The position peaked at $10.1M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • KBC Group reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • KBC Group sold 3,726 Abiomed Inc shares in Q4 2022, an estimated $915K.
  • KBC Group first reported a position in Abiomed Inc in Q1 2015 and held it in 22 quarters.
  • KBC Group's Abiomed Inc position peaked at $10.1M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on KBC Group's 13F filing for Q4 2022, filed 13 Feb 2023.